China's Biocytogen gets $78m Series D
Chinese contract research organization (CRO) Biocytogen has raised a RMB543 million ($78 million) Series D round led by China Life Insurance and SDIC Venture Capital, a VC arm of the State Development & Investment Corporation (SDIC).
Existing investors CMB International – an investment arm of China Merchants Bank – Materia Medica Capital, and 3E Bioventures also participated in the funding round, according to a release. All three...
More on Greater China
Latest News
Hong Kong's Animoca raises $359m at $5b valuation
US-based Liberty City Ventures has led a USD 359m round for Hong Kong blockchain media company Animoca Brands at a pre-money valuation of USD 5bn, more than double its valuation in October.
China beauty retailer Harmay raises $200m
Harmay, a China-based omnichannel beauty products retailer, has raised USD 200m across Series C and D rounds.
TPG-owned clinical trials player raises new equity, debt
Novotech, an Asia-based clinical trials specialist controlled by TPG Capital, has secured USD 760m in new equity and debt financing at a post-deal valuation of approximately USD 3bn.
Quadrant exits Australia experiential tourism business
Quadrant Private Equity has sold Journey Beyond, an Australia-based experiential tourism business, to US-based Hornblower Group, which is best known for offering cruise and sightseeing packages.